Kyle T Floyd
Overview
Explore the profile of Kyle T Floyd including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
39
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Peczkowski K, Rastogi N, Lowe J, Floyd K, Schultz E, Karaze T, et al.
Front Physiol
. 2022 Jan;
12:820245.
PMID: 35069268
[This corrects the article DOI: 10.3389/fphys.2020.568909.].
2.
Peczkowski K, Rastogi N, Lowe J, Floyd K, Schultz E, Karaze T, et al.
Front Physiol
. 2020 Oct;
11:568909.
PMID: 33101056
Duchenne muscular dystrophy (DMD) is an X-linked disorder caused by the lack of functional dystrophin protein. In muscular dystrophy preclinical research, it is pertinent to analyze the force of the...
3.
Lowe J, Kadakia F, Zins J, Haupt M, Peczkowski K, Rastogi N, et al.
J Neuromuscul Dis
. 2018 Jul;
5(3):295-306.
PMID: 30010143
Background: Mineralocorticoid receptor antagonists added to angiotensin converting enzyme inhibitors have shown preclinical efficacy for both skeletal and cardiac muscle outcomes in young sedentary dystrophin-deficient mdx mice also haploinsufficient for...
4.
Lowe J, Floyd K, Rastogi N, Schultz E, Chadwick J, Swager S, et al.
J Neuromuscul Dis
. 2016 Nov;
3(3):395-404.
PMID: 27822449
Background: Combined treatment with an angiotensin-converting enzyme inhibitor and a mineralocorticoid receptor (MR) antagonist improved cardiac and skeletal muscle function and pathology in a mouse model of Duchenne muscular dystrophy....
5.
Lowe J, Wodarcyk A, Floyd K, Rastogi N, Schultz E, Swager S, et al.
J Neuromuscul Dis
. 2016 Apr;
2(3):257-268.
PMID: 27110493
Background: Angiotensin converting enzyme inhibitors (ACEi) are the current standard of care treatment for cardiac dysfunction in Duchenne muscular dystrophy patients. We previously showed treatment with an ACEi plus mineralocorticoid...